In MM, WT1 was demonstrated to serve as an additional marker for risk stratification.94 The TCRm-CAR construct was derived from a monoclonal TCRm antibody (WT1 28z) recognising a specific peptide of the WT1 protein in the context of HLA-A*02:01. Here, WT1 is linked to Miyoshi myopathy.